Laminine What is a Stem Cells call us @ +63932.848.8883
Laminine - is a Stem Cell Enhancer! Stem cells are the foundation for every organ, tissue and cell in the human body. Stem cells may be able to repair or rep...
By: Eddie Balanoba
See more here:
Laminine What is a Stem Cells call us @ +63932.848.8883 - Video
14 Month Results After Stem Cell Therapy by Dr Harry Adelson for Arthritic Hip
http://www.docereclinics 14 months after stem cell therapy for his arthritic hip, Marty discusses his results by Dr. Harry Adelson. Call the clinic today at ...
By: Harry Adelson, N.D.
Read more:
14 Month Results After Stem Cell Therapy by Dr Harry Adelson for Arthritic Hip - Video
Webinar: Reimbursement Strategies for Stem Cell Therapy Products
Planning Your Payment Strategy in Early Product Development EXPERT SPEAKERS: Michael Werner, J.D., Executive Director, Alliance for Regenerative Medicine;...
By: Fernanda Torres
Here is the original post:
Webinar: Reimbursement Strategies for Stem Cell Therapy Products - Video
Las Vegas, NV (PRWEB) February 05, 2014
Global Stem Cells Group, Inc. and affiliate Stem Cell Training, Inc. were represented by Josepth Purita, M.D. at the 21st Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine in Las Vegas, Dec. 15, 2013. Purita, a lead trainer for Stem Cell Training, Inc. and a pioneer in the use of stem cell therapies in orthopedics, addressed more than 5,000 conference attendees with his presentation titled, Cutting Edge Concepts for the Regenerative Medicine Physician in the Use of Stem Cell & PRP Injections.
The record number of attendees gathered from around the world at the Venetian/Palazzo Resort in Las Vegas for three days to attend the prestigious conference hosted by the American Academy of Anti-aging Medicine. The conference featured physicians and medical personnel who practice and manage stem cell technology, certification, and pellet therapy to discuss brain health and offer case studies. Workshops on personalized lifestyle medicine and aesthetic medicine were also held.
Purita was joined by an illustrious group of speakers including: Author Judith Reichman, M.D., womens health care expert and specialist in gynecology, infertility and menopause; Travis Stork, M.D., ER physician and host of the Emmy Award-winning talk show, The Doctors; and Actress and Author Suzanne Somers, a dedicated health advocate and proponent of alternative and integrative medicine.
Former California Gov. Arnold Schwarzenegger accepted the 2013 A4M Infinity Award at Saturday afternoons general session for his progressive leadership role in early funding and support of stem cell research and healthcare reform. Somers presentation Our Time Has Come, discussing the medical needs of the rapidly aging baby-boom population. Stork, host of the Emmy-Award-winning medical talk show The Doctors, discussed long-term health in a speech called Your Best Life. Reichmans presentation titled Slow Your Clock Down: On- Label, Off- Label, Gray- Label, discussed the importance on maintain balance and living a healthy lifestyle.
For more information on the World Congress on Anti-Aging, Regenerative and Aesthetic Medicine, plus upcoming conferences and training programs around the world, visit the A4M website, email, bnovas(at)regenestem(dot)com or call 849.943.2988.
About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
The Global Stem Cell Foundation was formed as a nonprofit charitable organization that aims to fund research on the expanding need for stem cell solutions for patients, and identify best practices between physicians engaged in stem cell treatments in the U.S. and around the world.
Continue reading here:
Joseph Purita, M.D. of Global Stem Cells Group, Inc. Featured Speaker at 21st Annual World Congress on Anti-Aging ...
therapy treatment for stem cell therapy treatment for cerebral palsy by dr alok sharma, mumbai,
improvement seen in just 5 days after stem cell therapy treatment for cerebral palsy by dr alok sharma, mumbai, india. Stem Cell Therapy done date 31 Dec 201...
By: Neurogen Brain and Spine Institute
Read the original post:
therapy treatment for stem cell therapy treatment for cerebral palsy by dr alok sharma, mumbai, - Video
Stem cells repair damaged meniscus tissue
http://www.stemcellsarthritistreatment.com A single stem cell injection following meniscus knee surgery may provide pain relief and aid in meniscus regrowth, according to a novel study appearing...
By: Nathan Wei
Read this article:
Stem cells repair damaged meniscus tissue - Video
Stem Cell Research Acid Solution Blood Cells Embryonic Stem Cells
Stem Cell Research Acid Solution Blood Cells Embryonic Stem Cells.
By: News Footage
Excerpt from:
Stem Cell Research Acid Solution Blood Cells Embryonic Stem Cells - Video
Jacco van Rheenen from Hubrecht Institute and UMC Utrecht talks about cancer stem cells
Dr. Jacco van Rheenen from Hubrecht Institute and UMC Utrecht received in December 2013 the Stem Cells Young Investigator Award for an article about cancer s...
By: Federico Rodriguez
More:
Jacco van Rheenen from Hubrecht Institute and UMC Utrecht talks about cancer stem cells - Video
REGULATED INFORMATION FEBRUARY 4, 2014
TiGenix reaches major cell therapy milestone with 1000th implant of ChondroCelect
Leuven (BELGIUM) - February 4, 2014 - TiGenix (NYSE Euronext: TIG), a leader in the field of cell therapy, announced today that it reached a major milestone with the performance of the 1000th ChondroCelect implantation for cartilage repair in the knee. ChondroCelect is the first cell therapy that was granted approval by the European Medicines Agency (EMA) as an Advanced Therapy Medicinal Product (ATMP). Today it is routinely used in orthopedic centers of excellence across several European countries.
"A 1000 patients have already benefited from this innovative therapy, further supporting its efficacy and safety profile," said Eduardo Bravo, CEO of TiGenix. "A milestone such as today's is a clear demonstration of how far the cell therapy field has progressed over recent years, and I have no doubt that it is on its way to become a mainstay in clinical practice. We will continue to work towards turning our ChondroCelect franchise into a cash flow positive asset, and to push the clinical development of our pipeline of stem cell programs to a successful conclusion."
About ChondroCelect An innovative treatment, ChondroCelect has been shown to result in long-term durable clinical benefits in patients with recent cartilage lesions. Five-year follow-up data confirm that the therapeutic effect and the clinical benefit of ChondroCelect gained over baseline is maintained up to at least five years after the cartilage repair intervention. In addition, the data confirm that early treatment with ChondroCelect results in a superior clinical benefit over microfracture, and a lower failure rate.
Cartilage lesions of the knee are a frequent cause of disability in the active population. Caused by repetitive microtraumata, or due to sports or traffic accidents, cartilage lesions rarely heal spontaneously. When untreated, they predispose to osteoarthritis, which causes disability and represents a major socioeconomic burden. A treatment that allows symptom relief and functional recovery is key. To meet this important medical need, TiGenix developed ChondroCelect, the first cell therapy that was granted approval by the EMA as an ATMP.
ChondroCelect is administered to patients in an autologous chondrocyte implantation procedure known as Characterized Chondrocyte Implantation. TiGenix has designed a sophisticated manufacturing process to preserve the cells' characteristics and biological activity, and to maintain their ability to produce high quality cartilage. This process meets the highest quality standards and has been approved by the EMA.
For more information: Eduardo Bravo Chief Executive Officer eduardo.bravo@tigenix.com
Claudia D'Augusta Chief Financial Officer claudia.daugusta@tigenix.com
About TiGenix
View original post here:
TiGenix : reaches major cell therapy milestone with 1000th.
Editors note: What follows is a guest post. Michael Zhang is an MD-PhD student studying at the University of Louisville School of Medicine. He is one of my go-to experts on matters of cell biology and stem cells. (His bio is below.)
As you may have heard, this week brought striking news in the field of stem cell biology. Researchers from Boston and Japan published two papers in the prestigious journal Nature in which they describe new and easy ways to transform mouse cells back into stem cells. (NPR coverage here.) Make no mistake, this is not mundane science news. This is big.
I follow cell biology because I believe it is the branch of science that will bring the next major advance in modern medicine. Rather than implant a pacemaker, future doctors may inject a solution of sinus node stem cells, and voila, the heart beats normally. Rather than watch a patient with a scarred heart die of heart failure or suffer from medication side effects, future doctors may inject stem cells that replace the non-contracting scar. And the same could happen for kidneys, pancreas, spinal nerves, etc.
When I heard the news, I emailed Michael the link with the following subject line: This is pretty cool, right? He wrote back. What he taught me is worth sharing.
***
Michael Zhang MD-PhD candidate Univ of Louisville
By Michael Zhang:
Japanese and American cell biologists have recently reported dramatic new findings that are likely to upend biological dogma.
For much of the past century, the prevailing consensus held that once animal cells move past the earliest embryonic stages, they are irreversibly committed to specialized roles in the adult brain cells, heart cells, lung cells etc. In the past decade, two Nobel-winning biologists each separately demonstrated that committed specialist cells (aka differentiated cells) could be reprogrammed back to a primordial, embryonic state (aka pluripotent stem cell) that could then morph into any new type of specialized cell.
Now, Professor Obokata and her colleagues describe new methods to induce this reprogramming of specialized cells to (pluripotent) stem cells. Whereas previous methods involved draconian procedures the transfer of entire nuclei between cells, or the transfer of multiple genes Obokatas group found that simply squeezing a terminally differentiated cell, or immersing it in an acidic solution, could induce reprogramming to an embryonic stem cell state.
Read more from the original source:
Progress in stem cell biology: This could change everything about the practice of medicine
stem cell therapy treatment for traumatic brain injury by dr alok sharma, mumbai, india
improvement seen in just 5 days after stem cell therapy treatment for traumatic brain injury by dr alok sharma, mumbai, india. Stem Cell Therapy done date 7 ...
By: Neurogen Brain and Spine Institute
See the original post:
stem cell therapy treatment for traumatic brain injury by dr alok sharma, mumbai, india - Video
PHOENIX, Ariz. -
Stem cell research and therapy on humans has traveled a long and often politically troubled path.
Not so for pets, where stem cell treatment has been used for nearly 10 years and now it is so routine, and so successful, it can be done in a day.
Ava is a 90 pound, 2-year-old Akita, who is about to undergo stem cell surgery. A little IV, a little anesthesia and Ava is out.
"It is used for arthritis mostly," said Dr. Velvet Edwards.
Ava is just beginning her day at Pecan Grove Veterinary Hospital in Tempe. Dr. Edwards oversees the stem cell procedure.
"Stem cells are healing cells, so they seek out area of injury damage or destruction," explained Edwards. "They accelerate healing and help the animal, the patient, the pet just use their own natural abilities to get better."
Veterinary stem cells are harvested from the animal's own fat cells. They are separated and processed by machinery right inside the vet's office and then injected back into the dog's trouble spots.
Thanks to new technology developed by Meti Vet, the process is completed in just a day.
"The pet comes in the morning, it's anesthetized and I collect about two to four grams of fat usually behind the shoulder blade," said Edwards. "Then I hand that fat over to my technicians to run it through a series of steps.. basically to dissolve the fat and get down to a little stem cell pellet... Then we take that pellet and we reconstitute it and make it injectable. I will put it back into the animal's body wherever I need it later that day."
Continue reading here:
Stem cell treatment: Controversial for humans, but not for pets
4060AS JAPAN-STEM CELLS
4060AS JAPAN-STEM CELLS.
By: BYNTVNews
Go here to read the rest:
4060AS JAPAN-STEM CELLS - Video
ChurchMilitant.TV News 01-31
Today #39;s stories - Russia To Set Up Pregnancy Centers Al Gore: African Fertility Managed Scientists Replicate Embryonic Stem Cells Philippines Contraception W...
By: ChurchMilitantTV
Here is the original post:
ChurchMilitant.TV News 01-31 - Video
Douglas Melton on How to Grow a Heart: Transforming Stem Cells Into Live Organs
Doug Melton, Co-Director of the Harvard Stem Cell Institute, on the new frontier in biotechnology: creating human organs. Find out more at http://tinyurl.com...
By: traian eric
Go here to see the original:
Douglas Melton on How to Grow a Heart: Transforming Stem Cells Into Live Organs - Video
Stem cell technology and osteoarthritis... winning the war!
http://tinyurl.com/st0pagingn0w "We #39;ve explored the mysteries of the universe. However, there is another mystery closer to home. When an earthworm is cut in ...
By: Miranda Noiree
Read more:
Stem cell technology and osteoarthritis... winning the war! - Video
U Autologous Stem Cell Skin Care for Anti Aging - American Cryostem
http://tinyurl.com/q2egdra - With U Autologous stem cell skin care, along with adipose tissue storage, patients can now use their own fat stem cells for anti...
By: Gaspar mugur
More:
U Autologous Stem Cell Skin Care for Anti Aging - American Cryostem - Video
Contact Information
Available for logged-in reporters only
Newswise LA JOLLAThe Salk Institute for Biological Studies will join Stanford University in leading a new Center of Excellence in Stem Cell Genomics, created through a $40 million award by California's stem cell agency, the California Institute for Regenerative Medicine.
The center will bring together experts and investigators from seven different major California institutions to focus on bridging the fields of genomics the study of the complete genetic make-up of a cell or organism with cutting-edge stem cell research.
The goal is to use these tools to gain a deeper understanding of the disease processes in cancer, diabetes, endocrine disorders, heart disease and mental health, and ultimately to find safer and more effective ways of using stem cells in medical research and therapy.
"The center will provide a platform for collaboration, allowing California's stem cell scientists and genomics researchers to bridge these two fields," says Joseph Ecker, a Salk professor and Howard Hughes Medical Institute and Gordon and Betty Moore Foundation Investigator. "The Center will generate critical genomics data that will be shared with scientists throughout California and the rest of the world."
Ecker, holder of the Salk International Council Chair in Genetics, is co-director of the new center along with Michael Snyder, a professor and chair of genetics at Stanford.
Salk and Stanford will lead the center, and U.C. San Diego, Ludwig Institute for Cancer Research, the Scripps Research Institute, the J. Craig Venter Institute and Illumina Inc., all in San Diego, will collaborate on the project, in addition to U.C. Santa Cruz, which will also run the data coordination and management component.
"This Center of Excellence in Stem Cell Genomics shows why we are considered one of the global leaders in stem cell research," says Alan Trounson, president of the stem cell agency. "Bringing together this team to do this kind of work means we will be better able to understand how stem cells change as they grow and become different kinds of cells. That deeper knowledge, that you can only get through a genomic analysis of the cells, will help us develop better ways of using these cells to come up with new treatments for deadly diseases."
In addition to outside collaborations, the center will pursue some fundamental questions and goals of its own, including collecting and characterizing induced pluripotent stem cell lines from patients with familial cardiomyopathy; applying single-cell genomic techniques to better understand cellular subpopulations within diseased and healthy brain and pancreatic tissues; and developing novel computational tools to analyze networks underlying stem cell genome function.
See the original post:
Salk Institute and Stanford University to Lead New $40 Million Stem Cell Genomics Center
Contact Information
Available for logged-in reporters only
Newswise Researchers at the University of California, San Diego School of Medicine have identified a protein critical to hematopoietic stem cell function and blood formation. The finding has potential as a new target for treating leukemia because cancer stem cells rely upon the same protein to regulate and sustain their growth.
Hematopoietic stem cells give rise to all other blood cells. Writing in the February 2, 2014 advance online issue of Nature Genetics, principal investigator Tannishtha Reya, PhD, professor in the Department of Pharmacology, and colleagues found that a protein called Lis1 fundamentally regulates asymmetric division of hematopoietic stem cells, assuring that the stem cells correctly differentiate to provide an adequate, sustained supply of new blood cells.
Asymmetric division occurs when a stem cell divides into two daughter cells of unequal inheritance: One daughter differentiates into a permanently specialized cell type while the other remains undifferentiated and capable of further divisions.
This process is very important for the proper generation of all the cells needed for the development and function of many normal tissues, said Reya. When cells divide, Lis1 controls orientation of the mitotic spindle, an apparatus of subcellular fibers that segregates chromosomes during cell division.
During division, the spindle is attached to a particular point on the cell membrane, which also determines the axis along which the cell will divide, Reya said. Because proteins are not evenly distributed throughout the cell, the axis of division, in turn, determines the types and amounts of proteins that get distributed to each daughter cell. By analogy, imagine the difference between cutting the Earth along the equator versus halving it longitudinally. In each case, the countries that wind up in the two halves are different.
When researchers deleted Lis1 from mouse hematopoietic stem cells, differentiation was radically altered. Asymmetric division increased and accelerated differentiation, resulting in an oversupply of specialized cells and an ever-diminishing reserve of undifferentiated stem cells, which eventually resulted in a bloodless mouse.
What we found was that a large part of the defect in blood formation was due to a failure of stem cells to expand, said Reya. Instead of undergoing symmetric divisions to generate two stem cell daughters, they predominantly underwent asymmetric division to generate more specialized cells. As a result, the mice were unable to generate enough stem cells to sustain blood cell production.
The scientists next looked at how cancer stem cells in mice behaved when the Lis1 signaling pathway was blocked, discovering that they too lost the ability to renew and propagate. In this sense, the effect Lis1 has on leukemic self-renewal parallels its role in normal stem cell self-renewal, Reya said.
More here:
Split Decision: Stem Cell Signal Linked with Cancer Growth
Durham, NC (PRWEB) February 03, 2014
Previous studies have shown that multiple stem cell implantations might assist adults suffering from complete spinal cord injuries (SCI). Now a groundbreaking study released today in STEM CELLS Translational Medicine shows for the first time that children with SCI might benefit, too.
Marcin Majka, Ph.D., and Danuta Jarocha, Ph.D., led the study at Jagiellonian University College of Medicine in Krakow, Poland. "Although it was conducted on a small number of patients carrying a different injury level and type, preliminary results demonstrate the possibility of attaining neurological, motor and sensation and quality-of-life improvement in children with a chronic complete spinal cord injury through multiple bone marrow derived cell (BMNC) implantations. Intravenous implantations of these cells seem to prevent and/or help the healing of pressure ulcers," Dr. Majka said.
The study involved five children, ranging in age from 3 to 7, all of whom were patients at University Childrens Hospital in Krakow. Each had suffered a spinal cord injury at least six months prior to the start of the stem cell program and was showing no signs of improvement from standard treatments. The patients collectively underwent 19 implantation procedures with BM-derived cells, with every treatment cycle followed by an intensive four weeks of rehabilitation.
The children were evaluated over a one to six year period for sensation and motor improvement, muscle stiffness and bladder function. Any improvement in their quality of life was also noted, based on estimated functional recovery. Additionally, the development of neuropathic pain, secondary infections, urinary tract infections or pressure ulcers was tracked.
"Two of the five children receiving the highest number of transplantations demonstrated neurological and quality-of-life improvements," Dr. Jarocha said. "They included a girl who, before the stem cell implantations, had to be tube fed and needed a ventilator to breathe. She is now able to eat and breathe on her own."
The study also demonstrated no long-term side effects from the BMNCs, leading the researchers to conclude that single and multiple BMNCs implantations were safe for pediatric patients as well as adults.
Interestingly, when the scientists compared their study with those done on adults, the results did not suggest an advantage of the younger age. "This is somehow unexpected since the younger age should provide better ability to regenerate. Since the present study was done on a small number of patients, a larger study using the same methodology for pediatric and adult patients allowing a direct comparison should be performed to confirm or contradict the observation. Larger studies with patients segregated according to the type and level of the injury with the same infusion intervals should be performed to obtain more consistent data, too," Dr. Majka added.
"While this studys sample is small, it is the first to report the safety and feasibility of using bone marrow derived cells to treat pediatric patients with complete spinal cord injury," said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "The treatment resulted in a degree of neurological and quality-of-life improvement in the study participants."
The full article, "Preliminary study of autologous bone marrow nucleated cells transplantation in children with spinal cord injury," can be accessed at http://www.stemcellstm.com.
Original post:
First Study Tracking Stem Cell Treatments For Children With Spinal Cord Injuries Shows Potential Benefit